Skip to main content
. 2019 Jun;31(3):481–488. doi: 10.21147/j.issn.1000-9604.2019.03.10

S3.

S3

Kaplan-Meier curves for overall survival from the time of progressive disease and from the time of initial crizotinib treatment. (A,B) Crizotinib beyond progressive disease (CBPD) vs. non-CBPD: the median overall survival (OS) from the time of crizotinib progression was significantly longer in the CBPD group than in the non-CBPD group (P<0.001) and the median OS from the start of initial crizotinib treatment was also longer in the CBPD group than in the non-CBPD group (P<0.001); (C,D) Receipt of next-generationALK inhibitors vs. no receipt of next-generation ALK inhibitors: the median OS from the time of crizotinib progression was significantly longer in patients who received next-generation ALK inhibitors (P<0.001), and so was the median OS from the start of initial crizotinib treatment (P=0.004).